We Help Companies Find New Sales Opportunities
AstraZeneca is to invest £75m in a new warehouse and packing facility at its site in Macclesfield, securing the future of 3,500 jobs.
AstraZeneca has won permission from Cambridge City Council to build a new £330m headquarters for 2,000 staff by the end of 2016.
AstraZeneca is to buy US-based Bristol-Myers Squibb out of their diabetes treatments joint venture for up to £2.5bn, with the transfer of about 4,100 staff.
AstraZeneca is to relocate up to 400 research scientists to three temporary sites in Cambridge next year, in preparation for the 2016 opening of its new £330m headquarters.
AstraZeneca is to invest £120m in the development of a new Zoladex production facility at its site in Macclesfield by 2017, securing the future of 300 jobs.
AstraZeneca is to acquire Spirogen, the London-based drug development firm with 25 staff, for an initial £125m, in order to expand its MedImmune biologics division.
AstraZeneca has announced that its MedImmune biologics research division has acquired Spirogen, the biotechnology firm, for an initial £125m.
AstraZeneca has won permission to build a 70,000 sq ft finished formulation facility at its pharmaceutical plant in Macclesfield, with the creation of 36 jobs.
AstraZeneca has confirmed plans to develop a new £330m global headquarters for 2,000 staff at the Cambridge Biomedical Campus by 2016.
AstraZeneca has secured government funding of £5m to help develop a BioScience cluster at its Alderley Edge research site, in order to attract innovative pharmaceutical companies.
AstraZeneca is to acquire Ardea Biosciences, the US pharmaceuticals firm, for £782m.
AstraZeneca is to sell Astra Tech, its Sweden-based dental products business with 2,200 staff, to Dentsply International for about £1.1bn.
AstraZeneca is said to be planning to set up a 55,000 sq ft office at Stockley Park near Heathrow.
AstraZeneca is to acquire Novexel, the French infection research company, for up to £266m, and will collaborate with US-based Forest Laboratories in the development of two antibiotics.
AstraZeneca is planning to relocate its London headquarters from Mayfair to a 60,000 sq ft office in Paddington next year.
AstraZeneca has awarded a £45m contract to Mott MacDonald to build a four-storey research centre at its Alderley Park site in Cheshire.
AstraZeneca has appointed CB Richard Ellis to find a suitable 60,000 sq ft site for a new headquarters in London, and is expected to relocate from Stanhope Gate by 2010.
AstraZeneca is to acquire MedImmune, the US biotechnology company that is developing about 45 experimental drugs and flu vaccines and has almost 3,000 staff, for £7.7bn.
AstraZeneca has announced plans to invest a further £4.3m in the expansion of its pharmaceuticals testing laboratory in Brixham, Devon, by 2008.
AstraZeneca is to shed 700 of the 2,500 jobs at its pharmaceuticals factory in Macclesfield over the next three years, but has also announced plans to invest £63m in a new laboratory at the site.
AstraZeneca is to acquire Arrow Therapeutics, the London-based biotechnology company with 57 staff, for £76m, and has also announced plans to shed 3,000 jobs over the next three years.
AstraZeneca is planning to double the size of its recently-acquired Cambridge Antibody Technology subsidiary by extending its research into new disease areas, with the creation of 200 jobs.
AstraZeneca is planning to set up a £53m pharmaceuticals research centre in China by 2009.
AstraZeneca is to acquire Cambridge Antibody Technology, the Cambridge-based biotechnology company with 300 staff, for £700m.
AstraZeneca has won planning permission from Torbay Council for a new £9m four-storey laboratory building at its site in Brixham, securing the future of 90 jobs.
AstraZeneca is to set up a £21m pharmaceuticals manufacturing plant in Egypt in 2007, with the creation of 140 jobs.
AstraZeneca is investing £75m in Cambridge Antibody Technology, in order to co-operate in the development of anti-inflammatory drugs.
AstraZeneca and Royal Cosun are to sell their Advanta seeds business to Syngenta of Switzerland for £280m.
AstraZeneca is to invest £16m in new drug discovery facilities at its Charnwood site by 2006, with the creation of 75 scientific jobs, and has also provided details of a further investment at Alderley Park in Cheshire.
AstraZeneca is to invest £60m in Abgenix, the US biotechnology company, in order to collaborate in the area of antibody drug development.
AstraZeneca is planning to invest £19m in a new research facility in India to develop treatments for tuberculosis.
AstraZeneca has sold Marlow Foods, the manufacturer of Quorn substitute meat products, to Montagu Private Equity for £70m.
AstraZeneca is to set up a £40m screening centre at its Alderley Park site in Cheshire by next year, in order to boost research into cancer, diabetes and other illnesses.
AstraZeneca is to open a £69m pharmaceuticals plant in the Wuxi New District of China, where it will employ 280 people manufacturing products for the domestic market.
AstraZeneca is to acquire the rights to develop cancer treatment based on the work of Cyclacel in Dundee, in a £8m deal.
AstraZeneca has announced plans to invest £110m in new laboratory and office facilities at its Alderley Park research site near Macclesfield.
AstraZeneca has sold its dental anaesthetics business to Dentsply International of the US for £91m.
AstraZeneca is to invest £37m in the expansion of its Macclesfield plant, due to rising demand for its Seroquel treatment for schizophrenia.
AstraZeneca and Novartis are planning to dispose of a number of fungicide and herbicide products in order to win European approval for the merger of their agrochemicals businesses into a new company called Syngenta.
AstraZeneca and Novartis of Switzerland are to merge their agricultural chemicals operations, creating a new company called Syngenta that will be the world's biggest crop protection group.
AstraZeneca is selling its speciality chemicals business to a management buy-out backed by Cinven and Investcorp for £1.3bn.